Effect of L-arginine versus control group on the prevention of preeclampsia in primiparous pregnant women

Effect of L-arginine versus control group on the prevention of preeclampsia in primiparous pregnant women: a single-blind randomized controlled trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N416

Enrollment

172

Registered

2022-01-12

Start date

2022-01-30

Completion date

Unknown

Last updated

2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pre-eclampsia. Pre-eclampsia

Interventions

Intervention 1: Intervention group: Supplements (iron tablets and multivitamin capsules and calcium tablets) from 16th weeks of pregnancy once a day for 16 weeks plus L-arginine 500 mg tablets (manufa

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Age of 18 to 45 years; Primiparous: Singleton; Gestational age of 20 weeks;

Exclusion criteria

Exclusion criteria: History of hypertension; Affected with chronic diseases such as thyroid disorder and diabetes; Using selenium supplement;

Design outcomes

Primary

Measure	Time frame
Preeclampsia. Timepoint: Every two weeks until the end of pregnancy. Method of measurement: By taking a history (headache, blurred vision, epigastric pain, seizures), clinical examination (hypertension) and laboratory methods (oliguria, proteinuria, and increased liver enzymes).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Shahedeh Khansari

Hamedan University of Medical Sciences

dr_sh_kh@yahoo.com+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026